ATE223215T1 - Inhibitoren der fettsäuresynthese als antimikrobielle mittel - Google Patents

Inhibitoren der fettsäuresynthese als antimikrobielle mittel

Info

Publication number
ATE223215T1
ATE223215T1 AT95909239T AT95909239T ATE223215T1 AT E223215 T1 ATE223215 T1 AT E223215T1 AT 95909239 T AT95909239 T AT 95909239T AT 95909239 T AT95909239 T AT 95909239T AT E223215 T1 ATE223215 T1 AT E223215T1
Authority
AT
Austria
Prior art keywords
fatty acid
acid synthesis
inhibitors
fas
cells
Prior art date
Application number
AT95909239T
Other languages
English (en)
Inventor
James D Dick
Francis P Kuhajda
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE223215T1 publication Critical patent/ATE223215T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT95909239T 1994-01-24 1995-01-24 Inhibitoren der fettsäuresynthese als antimikrobielle mittel ATE223215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/188,421 US5614551A (en) 1994-01-24 1994-01-24 Inhibitors of fatty acid synthesis as antimicrobial agents
PCT/US1995/000544 WO1995019706A1 (en) 1994-01-24 1995-01-24 Inhibitors of fatty acid synthesis as antimicrobial agents

Publications (1)

Publication Number Publication Date
ATE223215T1 true ATE223215T1 (de) 2002-09-15

Family

ID=22693071

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909239T ATE223215T1 (de) 1994-01-24 1995-01-24 Inhibitoren der fettsäuresynthese als antimikrobielle mittel

Country Status (13)

Country Link
US (1) US5614551A (de)
EP (1) EP0738107B1 (de)
JP (1) JPH09508370A (de)
KR (1) KR100395601B1 (de)
AT (1) ATE223215T1 (de)
AU (1) AU703272B2 (de)
CA (1) CA2181031A1 (de)
DE (1) DE69528039T2 (de)
DK (1) DK0738107T3 (de)
ES (1) ES2182888T3 (de)
MX (1) MX9602934A (de)
PT (1) PT738107E (de)
WO (1) WO1995019706A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010881A (en) * 1996-02-20 2000-01-04 Smithkline Beecham Corporation RibG
US5859027A (en) * 1996-02-26 1999-01-12 Chektec Corporation Antimicrobial agent
US5910509A (en) * 1996-06-20 1999-06-08 Broedel; Sheldon E. Antimicrobial agent for agriculture
EP0918868A2 (de) * 1996-07-19 1999-06-02 Arch Development Corporation Antimikrobielle mittel, diagnostische reagenzien und impfstoffe auf der grundlage einzigartiger apicomplexanparasitenkomponenten
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
JP2000514308A (ja) * 1996-08-16 2000-10-31 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US20050112713A1 (en) * 1996-08-28 2005-05-26 Affinium Pharmaceuticals, Inc. Methods of using Fab I and compounds modulating Fab I activity
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5859028A (en) * 1997-04-28 1999-01-12 Potomax Limited Partnership Carotenoid synthesis inhibiting herbicides and fatty acid synthesis inhibiting oxime herbicides as anti-Apicomplexa protozoan parasite agents
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
JP4349744B2 (ja) * 1997-08-29 2009-10-21 ザ・ジョーンズ・ホプキンス・ユニバーシティ 抗菌化合物
US6713654B1 (en) 1997-08-29 2004-03-30 The Johns Hopkins University School Of Medicine Antimicrobial compounds
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US7303526B2 (en) * 1999-08-09 2007-12-04 Cardiokinetix, Inc. Device for improving cardiac function
EP1206463A4 (de) * 1999-08-23 2003-01-29 Smithkline Beecham Corp Inhibitoren der fettsäuresynthase
AR025976A1 (es) * 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
WO2001030988A1 (en) * 1999-10-27 2001-05-03 Smithkline Beecham Corporation Methods for making and using fatty acid synthesis pathway reagents
US6656703B1 (en) * 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
AU2761101A (en) * 2000-01-07 2001-07-24 Virginia Commonwealth University A scintillation proximity assay for type ii fatty acid biosynthetic enzymes
AU2001238515A1 (en) * 2000-02-16 2001-08-27 The John Hopkins University School Of Medicine Weight loss induced by reduction in neuropeptide y level
US20040157918A1 (en) * 2001-02-16 2004-08-12 Loftus Thomas M. Weight loss induced by reduction in neuropeptide y level
AU2001247755A1 (en) * 2000-03-23 2001-10-03 Millennium Pharmaceuticals, Inc. High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
US7048926B2 (en) * 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US6821999B2 (en) * 2001-11-21 2004-11-23 Kimberly-Clark Worldwide, Inc. Methods for inhibiting the production of TSST-1
US7348023B2 (en) * 2001-11-21 2008-03-25 Kimberly-Clark Worldwide, Inc. Absorbent articles containing additives
US7323186B2 (en) * 2001-11-21 2008-01-29 Kimberly-Clark Worldwide, Inc. Non-absorbent articles containing additives
US6955890B2 (en) * 2002-02-14 2005-10-18 Pyro Pharmaceuticals, Inc. Method for the identification and treatment of pathogenic microorganisms infections by inhibiting one or more enzymes in an essential metabolic pathway
US20060063224A1 (en) * 2002-05-10 2006-03-23 Schechter Alan M Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway
CN100513404C (zh) * 2002-07-09 2009-07-15 法斯根公司 新化合物、含该化合物的药物组合物以及该化合物的应用方法
CA2508792C (en) * 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
CA2532024A1 (en) * 2003-07-11 2005-01-20 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
BRPI0510397A (pt) * 2004-05-26 2007-11-13 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
EP1973902A2 (de) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamidverbindungen als fabi-inhibitoren und antibakterielle mittel
US20070244199A1 (en) * 2006-02-08 2007-10-18 Fasgen Inc. Anti-mycobacterial formulation
EP2687533B1 (de) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamidderivate als FAB-I-Hemmer
US8263613B2 (en) 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
KR20100031528A (ko) * 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
BR102012033811A8 (pt) * 2012-12-28 2019-12-24 Uniao Brasileira De Educacao E Assistencia Mantenedora Da Puc Rs compostos, uso, composição farmacêutica inibidora de redutase em microorganismos, ligante de inha, e, método para obtenção de ligantes de inha
BR102013006007A2 (pt) * 2013-03-13 2014-11-11 Ubea Compostos, uso, composição farmacêutica inibidora de redutase em microorganismos, ligante de inha, e, método para obtenção de ligantes de inha a partir de derivados de acetamida, ureia, fenol e carboxamida
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
US20210290629A1 (en) * 2016-07-07 2021-09-23 Forschungzentrum Borstel Leibniz-Zentrum fuer Medizin und Biowissenschaften Acc inhibitors for use in treating mycobacterial diseases
EP3266454A1 (de) * 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Acc-hemmer zur verwendung bei der behandlung von mycobakteriellen erkrankungen
US20210137934A1 (en) * 2017-03-16 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying myc-driven and lipogenesis-dependent neoplasms and methods of treating the same
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE252616C (de) * 1912-01-25 1912-10-23 Gebr Lesser Ablegerad für Kartoffelerntemaschinen mit einem quer zur Fahrrichtung de Maschine umlaufenden Wurfrad
US3535309A (en) * 1967-09-01 1970-10-20 Kitasato Inst Antibiotics and their production
US3630846A (en) * 1967-09-01 1971-12-28 Kitasato Inst And Toyo Jozo Kk Antibiotic production using streptomyces kitasatoensis
US3909361A (en) * 1971-06-29 1975-09-30 Nihon Tokushu Noyaku Seizo Kk Novel antifungal antibiotic substance, process for production of the same, and agricultural and horticultural fungicidal composition containing said substance
JPS5619344B2 (de) * 1972-11-11 1981-05-07
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4011334A (en) * 1975-10-03 1977-03-08 Richardson-Merrell Inc. Use of substituted furan and thiophene carboxaldehydes as hypolipidemic agents
US4738984A (en) * 1973-04-02 1988-04-19 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4110351A (en) * 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
US4000164A (en) * 1973-04-02 1976-12-28 Richardson-Merrell Inc. Hypolipidemic agents
US4032647A (en) * 1975-06-16 1977-06-28 Richardson-Merrell Inc. Substituted thenoylacetic acid and esters
US4328246A (en) * 1979-08-14 1982-05-04 Joseph Gold Anti Walker 256 carcinoma agent and combination thereof
JPS59225115A (ja) * 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS6058917A (ja) * 1983-09-09 1985-04-05 Rikagaku Kenkyusho 制癌剤
FR2552879B1 (fr) * 1983-10-03 1987-08-14 Pasteur Institut Procede et reactifs pour la detection d'une anomalie genetique dans une matiere biologique, notamment dans une preparation de leucocytes
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5110731A (en) * 1985-08-26 1992-05-05 Amgen, Inc. System for biotin synthesis
US4789630A (en) * 1985-10-04 1988-12-06 Cetus Corporation Ionic compounds containing the cationic meriquinone of a benzidine
GB8607137D0 (en) * 1986-03-21 1986-04-30 Efamol Ltd Compositions
US5188830A (en) * 1987-03-27 1993-02-23 Merck & Co., Inc. Methods for thrombolytic therapy
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
US5185149A (en) * 1987-03-27 1993-02-09 Merck & Co., Inc. Methods for thrombolytic therapy
JPH01132542A (ja) * 1987-11-19 1989-05-25 Toomen:Kk ゴッシポールラセミ体の光学分割法
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
JPH02113850A (ja) * 1988-10-21 1990-04-26 Nippon Oil & Fats Co Ltd 発癌抑制用油脂組成物
US5190969A (en) * 1988-12-20 1993-03-02 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents
AU621434B2 (en) * 1988-12-21 1992-03-12 Merrell Dow Pharmaceuticals Inc. Antiretroviral furan ketones
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
US5143907A (en) * 1991-05-10 1992-09-01 Boron Biologicals, Inc. Phosphite-borane compounds, and method of making and using the same
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1993012240A1 (en) * 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
JPH07509470A (ja) * 1992-07-24 1995-10-19 ザ・ジョーンズ・ホプキンス・ユニバーシティ がんの治療に脂肪酸合成阻害剤を用いる方法
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition

Also Published As

Publication number Publication date
DK0738107T3 (da) 2003-01-06
US5614551A (en) 1997-03-25
EP0738107A1 (de) 1996-10-23
EP0738107A4 (de) 1998-09-09
CA2181031A1 (en) 1995-07-27
PT738107E (pt) 2003-01-31
JPH09508370A (ja) 1997-08-26
MX9602934A (es) 1997-12-31
KR100395601B1 (ko) 2003-11-17
AU1726895A (en) 1995-08-08
WO1995019706A1 (en) 1995-07-27
AU703272B2 (en) 1999-03-25
DE69528039T2 (de) 2003-08-07
DE69528039D1 (de) 2002-10-10
ES2182888T3 (es) 2003-03-16
EP0738107B1 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
DE69528039D1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
DE69907508D1 (de) Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
IL135921A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
BG107537A (bg) Инхибиране на човешка tnf алфа активност
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
DE69332353D1 (de) Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
DE60039601D1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
AU2001245319A1 (en) Methods of treating diseases with activated protein c
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2002067851A3 (en) Method for treating fibrotic diseases or other indications iiic
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ATE258229T1 (de) Substanz fa-70d, herstellungsverfahren und verwendungen
TW200503624A (en) Preventive for plant disease and a method for preventing plant disease using the same
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0738107

Country of ref document: EP

REN Ceased due to non-payment of the annual fee